| Title |
A new perspective on metformin therapy in type 1 diabetes
|
|---|---|
| Published in |
Diabetologia, August 2017
|
| DOI | 10.1007/s00125-017-4364-6 |
| Pubmed ID | |
| Authors |
Rachel Livingstone, James G. Boyle, John R. Petrie, on behalf of The REMOVAL Study Team |
| Abstract |
Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease. |
X Demographics
The data shown below were collected from the profiles of 66 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 20 | 30% |
| Mexico | 4 | 6% |
| United States | 3 | 5% |
| Italy | 2 | 3% |
| India | 2 | 3% |
| Netherlands | 2 | 3% |
| Germany | 1 | 2% |
| Ghana | 1 | 2% |
| Guadeloupe | 1 | 2% |
| Other | 4 | 6% |
| Unknown | 26 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 47 | 71% |
| Practitioners (doctors, other healthcare professionals) | 12 | 18% |
| Scientists | 7 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 15% |
| Student > Ph. D. Student | 10 | 12% |
| Student > Master | 9 | 11% |
| Student > Bachelor | 9 | 11% |
| Researcher | 8 | 10% |
| Other | 18 | 22% |
| Unknown | 16 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 35% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Nursing and Health Professions | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Engineering | 3 | 4% |
| Other | 11 | 13% |
| Unknown | 24 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 65. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2024.
All research outputs
#652,930
of 25,394,081 outputs
Outputs from Diabetologia
#326
of 5,346 outputs
Outputs of similar age
#13,689
of 327,252 outputs
Outputs of similar age from Diabetologia
#20
of 94 outputs
Altmetric has tracked 25,394,081 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,252 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.